https://techcrunch.com/2022/07/15/nucleus-genomics-lands-new-funding-from-alexis-ohanian-to-help-people-assess-specific-disease-risks/

Nucleus Genomics, a genetic testing company focused on calculating a patient’s risk of certain diseases, is adding $14 million on to their initial seed funding round. With this round the company has raised, in total, $17.5 million.

This “seed plus” funding round was led by Alexis Ohanian’s 776. Ohanian is joining investors like Founders Fund, Adrian Aoun (CEO at Forward Health), Brent Saunders (former CEO at Allergan), Matteo Franceschetti (CEO at Eight Sleep), and others. Nucleus originally announced a $3.5 million seed round back in December of 2021.